The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LIVTENCITY (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
LIVTENCITY
Date registered
Evaluation commenced
Decision date
Approval time
155 (255 working days)
Active ingredients
maribavir
Registration type
NCE/NBE
Indication
LIVTENCITY (film coated tablet) is indicated for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies (see 4.3 CONTRAINDICATIONS and, 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).